Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Healthcare Sector Analysis

UpdatedJun 26, 2026
DataAggregated Company Financials
Companies1400
  • 7D4.3%
  • 3M11.0%
  • 1Y18.3%
  • YTD1.3%

AbbVie is up 12%, leading the way for the Healthcare industry, which has gained 4.3%. In the same time, Pfizer was down 6.1%. In the last 12 months, the industry was up 18%. Looking forward, earnings are forecast to grow by 18% annually.

Sector Valuation and Performance

Has the U.S. Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 26 Jun 2026US$6.6tUS$3.3tUS$121.7b24.3x53.9x2x
Sun, 24 May 2026US$6.4tUS$3.3tUS$122.9b23.4x51.9x1.9x
Tue, 21 Apr 2026US$6.4tUS$3.3tUS$121.1b24.3x52.4x1.9x
Thu, 19 Mar 2026US$6.2tUS$3.3tUS$124.4b23x50.1x1.9x
Sat, 14 Feb 2026US$6.5tUS$3.3tUS$126.4b26.8x51.4x2x
Mon, 12 Jan 2026US$6.6tUS$3.2tUS$136.3b26.5x48.5x2.1x
Wed, 10 Dec 2025US$6.2tUS$3.2tUS$133.9b25.5x46.7x2x
Fri, 07 Nov 2025US$6.0tUS$3.2tUS$131.7b24.3x45.6x1.9x
Sun, 05 Oct 2025US$6.0tUS$3.1tUS$137.8b24.7x43.8x2x
Tue, 02 Sep 2025US$5.7tUS$3.1tUS$137.5b23.3x41.4x1.8x
Thu, 31 Jul 2025US$5.5tUS$3.1tUS$126.6b24.1x43.5x1.8x
Sat, 28 Jun 2025US$5.5tUS$3.0tUS$127.5b24.8x43.1x1.8x
Mon, 26 May 2025US$5.3tUS$3.0tUS$126.9b22.6x41.7x1.7x
Wed, 23 Apr 2025US$5.2tUS$2.7tUS$97.7b24.5x53x2x
Fri, 21 Mar 2025US$5.7tUS$2.6tUS$81.5b26.8x70.3x2.2x
Sun, 16 Feb 2025US$5.8tUS$2.6tUS$82.1b26.8x70.8x2.2x
Tue, 14 Jan 2025US$5.8tUS$2.9tUS$78.9b28.2x74x2x
Thu, 12 Dec 2024US$6.0tUS$2.9tUS$77.5b28.1x78x2.1x
Sat, 09 Nov 2024US$6.2tUS$2.9tUS$75.9b28.3x82.1x2.1x
Mon, 07 Oct 2024US$6.2tUS$2.8tUS$60.0b29.7x102.5x2.2x
Wed, 04 Sep 2024US$6.3tUS$2.8tUS$60.4b31.1x104.9x2.2x
Fri, 02 Aug 2024US$6.4tUS$2.9tUS$68.5b32.9x92.7x2.2x
Sun, 30 Jun 2024US$6.2tUS$2.8tUS$62.2b30.5x99.3x2.2x
Tue, 28 May 2024US$6.1tUS$2.8tUS$63.7b30.9x96.4x2.2x
Thu, 25 Apr 2024US$6.0tUS$2.8tUS$84.1b31.3x71.8x2.2x
Sat, 23 Mar 2024US$6.2tUS$2.8tUS$82.1b31.8x75.9x2.2x
Mon, 19 Feb 2024US$6.3tUS$2.8tUS$82.4b30.1x75.9x2.2x
Wed, 17 Jan 2024US$6.4tUS$2.8tUS$90.8b32.2x70.2x2.3x
Fri, 15 Dec 2023US$6.1tUS$2.8tUS$91.5b32.5x67.1x2.2x
Sun, 12 Nov 2023US$5.7tUS$2.8tUS$91.0b26.5x62.1x2x
Tue, 10 Oct 2023US$5.9tUS$2.8tUS$98.3b26.1x59.9x2.1x
Thu, 07 Sep 2023US$6.0tUS$2.8tUS$98.6b27.5x61x2.2x
Sat, 05 Aug 2023US$6.1tUS$2.8tUS$100.7b28.8x60.6x2.2x
Mon, 03 Jul 2023US$6.1tUS$2.7tUS$110.3b26.6x54.9x2.2x
Price to Earnings Ratio

54.9x


Total Market Cap: US$6.1tTotal Earnings: US$110.3bTotal Revenue: US$2.7tTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Healthcare Sector Price to Earnings3Y Average 65.4x202420252026
Current Industry PE
  • Investors are pessimistic on the American Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 53.9x which is lower than its 3-year average PE of 65.4x.
  • The industry is trading close to its 3-year average PS ratio of 2.1x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 3.3% per year over the last three years.
  • Revenues for these companies have grown 7.0% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare sector?

US Market-2.68%
Healthcare4.33%
Life Sciences8.95%
Biotech5.05%
Pharma4.07%
Healthcare Services3.84%
Medical Equipment2.15%
Healthtech2.06%
Industry PE
  • Investors are most optimistic about the Life Sciences industry even though it's trading below its 3-year average PE ratio of 56.2x.
    • Analysts are expecting annual earnings growth of 16.9%, which is higher than its past year's earnings growth of 5.2% per year.
Forecasted Growth
  • Analysts are most optimistic on the Biotech industry, expecting annual earnings growth of 25% over the next 5 years.
  • However this is lower than its past earnings growth rate of 55% per year.
  • In contrast, the Pharma industry is expected to see its earnings grow by 15% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ABBV AbbVieUS$243.1412.3%
+US$47.1b		30.2%PE119.5x
JNJ Johnson & JohnsonUS$244.887.2%
+US$39.7b		61.1%PE28x
MRK MerckUS$125.4510.2%
+US$28.6b		59.1%PE34.7x
LLY Eli LillyUS$1.13k2.7%
+US$26.0b		41.8%PE39.8x
TMO Thermo Fisher ScientificUS$505.758.9%
+US$15.3b		22.7%PE27.4x

Latest News

PFE
US$23.67
Pfizer
7D
-6.1%
1Y
-2.4%
LLY
US$1,127.69
Eli Lilly
7D
2.7%
1Y
41.8%
ABT
US$93.24
Abbott Laboratories
7D
5.5%
1Y
-30.2%
BSX
US$44.20
Boston Scientific
7D
-2.4%
1Y
-57.7%
Seeking Alpha • 18h

Boston Scientific's Fall From Penthouse To Doghouse Creates A Value Opportunity

Summary Boston Scientific has suffered a 50% share price decline amid decelerating growth and competitive threats, but fundamentals-based valuation now appears attractive. Growth in key segments like electrophysiology and Watchman has slowed due to increased competition, reimbursement cuts, and less impressive clinical trial data. Management now guides to sub-10% revenue growth (6.5%-8% for the year), but I still expect 7.5% annualized growth over five years and improving margins. BSX shares are undervalued below the high $50s to low $60s; rerating requires consistent execution and no further cuts to guidance. Read the full article on Seeking Alpha
HIMS
US$32.71
Hims & Hers Health
7D
-7.8%
1Y
-29.3%
ABBV
US$243.14
AbbVie
7D
12.3%
1Y
30.2%
RGC
US$7.49
Regencell Bioscience Holdings
7D
-37.6%
1Y
-62.9%
DHR
US$193.21
Danaher
7D
9.1%
1Y
-4.1%
MRK
US$125.45
Merck
7D
10.2%
1Y
59.1%
MRNA
US$59.75
Moderna
7D
-6.6%
1Y
117.0%
AXSM
US$237.33
Axsome Therapeutics
7D
-5.3%
1Y
131.4%
Narrative Update • Jun 24

AXSM: Alzheimer’s Agitation Launch And CNS Pipeline Will Shape Future Outlook

Axsome Therapeutics' analyst fair value target has been raised from $270.28 to $276.47. Analysts point to updated expectations for Auvelity's growth potential, including the recently discussed Alzheimer's disease agitation indication and broader adoption across depression patients, as key drivers behind the shift.
ISRG
US$399.69
Intuitive Surgical
7D
-1.7%
1Y
-25.2%
Narrative Update • Jun 23

ISRG: Sector Reset And Recalls Will Temper Strong Utilization Outlook

Intuitive Surgical's internal fair value estimate has been revised slightly lower to about $413 from roughly $430, as analysts reflect a sector wide reset in price targets tied to lower procedure utilization expectations and tighter assumptions around future medical technology margins. Analyst Commentary Recent Street research around Intuitive Surgical points to a more cautious tone, even from generally constructive voices.
DXCM
US$68.65
DexCom
7D
-5.3%
1Y
-19.3%
UNH
US$415.53
UnitedHealth Group
7D
3.6%
1Y
37.3%
JNJ
US$244.88
Johnson & Johnson
7D
7.2%
1Y
61.1%
TMO
US$505.75
Thermo Fisher Scientific
7D
8.9%
1Y
22.7%
Analysis Article • Jun 17

Thermo Fisher Scientific (TMO) Stock Could Be 23% Below Fair Value After Neutral Rating

Piper Sandler’s new Neutral rating on Thermo Fisher Scientific (TMO), alongside a Material Transfer Agreement with Polymer Factory Sweden AB, has drawn fresh attention to how the stock reflects industry conditions and emerging technology partnerships. See our latest analysis for Thermo Fisher Scientific. Thermo Fisher Scientific’s latest share price of $472.63 sits against a mixed backdrop, with the stock down 20.23% on a year to date share price basis but delivering a 21.55% total...